Health Care

Amgen grew product sales 9% to $9.5 billion on volume in Q2 2026 and raised full-year guidance, but its 65% jump in reported EPS is mostly Horizon acquisition amortization rolling off — adjusted EPS rose 4%, and guidance implies second-half revenue growth slowing to about 4% as Prolia and XGEVA biosimilar erosion accelerates.

Align Technology grew Q2 2026 revenue 4.3% to $1.06 billion on 7.4% higher clear aligner case volume, but a $38.7 million legal and UK VAT charge pushed operating income down 5.5% and net income down 13.1%.

AbbVie grew revenue 12.4% to $15.0bn and lifted adjusted EPS 7.7% to $2.65, but reported EPS fell 46% to $0.39 on a $2.4bn contingent-consideration charge triggered by its own raised Skyrizi forecast and a $650m RemeGen licence payment.

Abbott closed its $20.6bn Exact Sciences acquisition eight days before quarter-end, and the deal costs cut GAAP EPS to $0.61 while underlying sales grew just 3.7% — Medical Devices up 8.1% ex-FX against Nutrition down 7.7%.

Agilent grew revenue 8.1% to $1.88 billion in fiscal Q3 2026 and lifted full-year guidance, but a $20 million tariff refund supplied about a third of the margin expansion and a prior-year tax one-off masks 21% pre-tax profit growth.

Revenue grew 9.5% on constant currency as Skyrizi and Rinvoq (both +24%) continue to outrun Humira's decline (-36%); GAAP EPS growth of 290% is a base-effect artifact of intangible amortization and contingent-consideration accounting, not operating performance.

Reported sales grew 13.0% but organic growth was 4.8%; the Exact Sciences acquisition drives most of the gap, and $658M of quarterly intangible amortization plus a $385M litigation reserve explain why GAAP EPS ($0.53) is less than half of adjusted EPS ($1.31).